drugset / Trial / NCT03922477
A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This Phase Ib study is designed to evaluate the safety and pharmacokinetics of atezolizumab when given in combination with Hu5F9-G4 to patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).
Timeline
- Start
- 2019-10-08
- Primary completion
- 2020-11-03
- Completion
- 2020-11-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Magrolimab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Magrolimab | Monoclonal antibody | 30 mg/kg | Intravenous |